Response rates in the IRd and placebo-Rd groups according to cytogenetic subgroup
| . | Overall response rate, n (%) . | VGPR or better, n (%) . | CR or better, n (%) . | |||
|---|---|---|---|---|---|---|
| Patients (N, ixazomib vs placebo group) . | IRd . | Placebo-Rd . | IRd . | Placebo-Rd . | IRd . | Placebo-Rd . |
| All (360 vs 362) | 282 (78) | 259 (72) | 173 (48) | 141 (39) | 42 (12) | 24 (7) |
| Standard risk (199 vs 216) | 160 (80) | 158 (73) | 191 (51) | 94 (44) | 24 (12) | 16 (7) |
| High risk* (75 vs 62) | 59 (79) | 37 (60) | 34 (45) | 13 (21) | 9 (12) | 1 (2) |
| del(17p)† (36 vs 33) | 26 (72) | 16 (48) | 14 (39) | 5 (15) | 4 (11) | 0 |
| t(4;14) alone (36 vs 25) | 32 (89) | 19 (76) | 19 (53) | 7 (28) | 5 (14) | 1 (4) |
| Amp 1q21 alone (80 vs 92) | 57 (71) | 63 (62) | 35 (44) | 37 (40) | 7 (9) | 8 (9) |
| Expanded high risk‡ (155 vs 154) | 116 (75) | 100 (65) | 69 (45) | 50 (33) | 16 (10) | 9 (6) |
| . | Overall response rate, n (%) . | VGPR or better, n (%) . | CR or better, n (%) . | |||
|---|---|---|---|---|---|---|
| Patients (N, ixazomib vs placebo group) . | IRd . | Placebo-Rd . | IRd . | Placebo-Rd . | IRd . | Placebo-Rd . |
| All (360 vs 362) | 282 (78) | 259 (72) | 173 (48) | 141 (39) | 42 (12) | 24 (7) |
| Standard risk (199 vs 216) | 160 (80) | 158 (73) | 191 (51) | 94 (44) | 24 (12) | 16 (7) |
| High risk* (75 vs 62) | 59 (79) | 37 (60) | 34 (45) | 13 (21) | 9 (12) | 1 (2) |
| del(17p)† (36 vs 33) | 26 (72) | 16 (48) | 14 (39) | 5 (15) | 4 (11) | 0 |
| t(4;14) alone (36 vs 25) | 32 (89) | 19 (76) | 19 (53) | 7 (28) | 5 (14) | 1 (4) |
| Amp 1q21 alone (80 vs 92) | 57 (71) | 63 (62) | 35 (44) | 37 (40) | 7 (9) | 8 (9) |
| Expanded high risk‡ (155 vs 154) | 116 (75) | 100 (65) | 69 (45) | 50 (33) | 16 (10) | 9 (6) |